IMPROD双参数MRI联合PSA密度诊断前列腺癌的外部验证
该研究在499例接受IMPROD bpMRI后行系统穿刺(Likert 3-5分者加靶向穿刺)的男性中外部验证既往活检策略。IMPROD bpMRI Likert 3-5和4-5分的sPCa阴性预测值分别为93%和92%,阳性预测值分别为57%和72%。DCA显示最佳组合为Likert 4-5或Likert 3且PSAd≥0.20 ng/ml/cm3,可避免35%活检但漏诊6%的sPCa。
要点
- IMPROD bpMRI对sPCa阴性预测值良好(Likert 4-5分92%)
- PSAd额外价值有限,主要在MRI可疑不明确者中改善阴性预测值
- 最佳组合策略可避免35%活检但漏诊6%的sPCa
核心结论
- IMPROD bpMRI对sPCa显示良好的阴性预测值,但PSAd的额外价值仅为边缘性。
研究设计与样本
- 在两个前瞻性bpMRI试验队列中外部验证既往活检策略,共499例男性接受IMPROD bpMRI后系统经直肠前列腺穿刺,Likert 3-5分者加2-4针靶向穿刺。
主要发现
- IMPROD bpMRI Likert 3-5分和4-5分组的sPCa阴性预测值分别为93%和92%,阳性预测值分别为57%和72%。
- 决策曲线分析中最佳组合为IMPROD bpMRI Likert 4-5分或Likert 3分且PSAd≥0.20 ng/ml/cm3,其阴性预测值93%、阳性预测值67%。
- 使用该组合,35%的研究患者可避免活检,但会漏诊13例sPCa(占所有诊断sPCa的6%,13/229)。
- IMPROD bpMRI Likert 4-5分组与最佳组合策略相比,阴性预测值92% vs 93%,阳性预测值72% vs 67%。
关键数值与推荐
- sPCa定义为Gleason评分≥3+4。
- IMPROD bpMRI Likert 3-5分组:阴性预测值93%,阳性预测值57%。
- IMPROD bpMRI Likert 4-5分组:阴性预测值92%,阳性预测值72%。
- 最佳组合(Likert 4-5或Likert 3且PSAd≥0.20 ng/ml/cm3):阴性预测值93%,阳性预测值67%,避免35%活检,漏诊6%(13/229)sPCa。
临床怎么用
- 对于IMPROD bpMRI Likert 4-5分的男性,可考虑直接活检,PSAd附加价值有限。
- 对于Likert 3分(可疑不明确)的男性,联合PSAd≥0.20 ng/ml/cm3可改善阴性预测值并减少活检。
- 采用最佳组合策略需权衡避免35%活检与漏诊6% sPCa的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biparametric magnetic resonance imaging (bpMRI) combined with prostate-specific antigen density (PSAd) may be an effective strategy for selecting men for prostate biopsy. It has been shown that performing biopsy only for men with bpMRI Likert scores of 4-5 or PSAd ≥0.15 ng/ml/cm3 is the most efficient strategy. OBJECTIVE: To externally validate previously published biopsy strategies using two prospective bpMRI trial cohorts. DESIGN, SETTING, AND PARTICIPANTS: After IMPROD bpMRI, 499 men had systematic transrectal prostate biopsies and men with IMPROD bpMRI Likert scores of 3-5 had an additional two to four targeted biopsies. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Various IMPROD bpMRI Likert score and PSAd thresholds were assessed using detection rates for significant prostate cancer (sPCa; Gleason score ≥3 + 4), predictive values, and proportion of biopsies avoided. Net benefits and decision curve analyses (DCA) were compared with the aim of finding an optimal strategy for sPCa detection. Combined biopsies were used for reference. RESULTS AND LIMITATIONS: The negative predictive value (NPV) for sPCa in IMPROD bpMRI Likert 3-5 and 4-5 score groups was 93% and 92%, respectively, while the corresponding positive predictive value (PPV) was 57% and 72%, respectively. In DCA, the optimal combination was IMPROD bpMRI Likert score 4-5 or Likert 3 with PSAd ≥0.20 ng/ml/cm3, which had NPV of 93% and PPV of 67%. Using this combination, 35% of the study patients would have avoided biopsies and 13 sPCas (6%, 13/229, of all sPCas diagnosed) would have been missed. CONCLUSIONS: IMPROD bpMRI demonstrated a good NPV for sPCa. PSAd improved the NPV mainly among men with equivocal suspicion on IMPROD bpMRI. However, the additional value of PSAd was marginal: the NPV and PPV for IMPROD bpMRI Likert 4-5 score group were 92% and 72%, respectively, while the corresponding values for the best combination strategy were 93% and 67%. PATIENT SUMMARY: We investigated a rapid prostate magnetic resonance imaging protocol (IMPROD bpMRI) combined with prostate-specific antigen (PSA) density for detection of significant prostate cancer. Our results show that IMPROD bpMRI is a good diagnostic tool, but the additional value provided by PSA density is marginal.
引用
- Knaapila J, Jambor I, Perez IM, et al. Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. Eur Urol Oncol. 2019. PMID: 31501082. doi:10.1016/j.euo.2019.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。